Shaleigh Smith
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Shaleigh Smith has a total of 140 co-authors. Here are the top co-authors by number of shared publications:
- Bhumika Jadeja
Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York
36 shared publications - Ciara M. Kelly
Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York
36 shared publications - Cristina R. Antonescu
Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY
36 shared publications - Samuel Singer
Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York
36 shared publications - William D. Tap
Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
36 shared publications - Josephine Kamtai Dermawan
Department of Pathology and Laboratory Medicine Cleveland Clinic Cleveland Ohio USA
35 shared publications
Latest Publications
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S5 from Novel Genomic Risk Stratification Model for Primary Gastrointestinal Stromal Tumors (GIST) in the Adjuvant Therapy Era
Supplementary Figure S5. RFS in primary localized gastric GIST excluding SDH-deficient cases.
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S5 from Novel Genomic Risk Stratification Model for Primary Gastrointestinal Stromal Tumors (GIST) in the Adjuvant Therapy Era
Supplementary Figure S5. RFS in primary localized gastric GIST excluding SDH-deficient cases.
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from Novel Genomic Risk Stratification Model for Primary Gastrointestinal Stromal Tumors (GIST) in the Adjuvant Therapy Era
Supplementary Figure 1. Traditional risk stratification in primary gastric and small bowel GIST. Primary gastric (A-C) and small bowel (D-F) GISTs localized at diagnosis without prior neoadjuvant treatment are risk stratified into low, moderate, and high risk groups based on site, tumor size and mitotic rate using the Miettinen (also includes very low risk) (A, D), Fletcher (B, E) and Joensuu (C, F) risk stratification schemes (Miettinen 2006, Fletcher 2002, Joensuu 2008). Recurrence-free survival for patients in each of these risk groups is represented by Kaplan-Meier curves (global log-rank P) for all primary localized cases.
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from Novel Genomic Risk Stratification Model for Primary Gastrointestinal Stromal Tumors (GIST) in the Adjuvant Therapy Era
Supplementary Figure 1. Traditional risk stratification in primary gastric and small bowel GIST. Primary gastric (A-C) and small bowel (D-F) GISTs localized at diagnosis without prior neoadjuvant treatment are risk stratified into low, moderate, and high risk groups based on site, tumor size and mitotic rate using the Miettinen (also includes very low risk) (A, D), Fletcher (B, E) and Joensuu (C, F) risk stratification schemes (Miettinen 2006, Fletcher 2002, Joensuu 2008). Recurrence-free survival for patients in each of these risk groups is represented by Kaplan-Meier curves (global log-rank P) for all primary localized cases.
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S4 from Novel Genomic Risk Stratification Model for Primary Gastrointestinal Stromal Tumors (GIST) in the Adjuvant Therapy Era
Supplementary Figure S4. RFS in primary localized gastric (A) and small bowel (B) GISTs by types of primary KIT and PDGFRA mutations [del: deletion; ex: exon; INS: insertion; PM: point mutation].
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S4 from Novel Genomic Risk Stratification Model for Primary Gastrointestinal Stromal Tumors (GIST) in the Adjuvant Therapy Era
Supplementary Figure S4. RFS in primary localized gastric (A) and small bowel (B) GISTs by types of primary KIT and PDGFRA mutations [del: deletion; ex: exon; INS: insertion; PM: point mutation].
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3 from Novel Genomic Risk Stratification Model for Primary Gastrointestinal Stromal Tumors (GIST) in the Adjuvant Therapy Era
Supplementary Figure 3. Genomic risk groups versus tumor size and mitotic rate.
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S3 from Novel Genomic Risk Stratification Model for Primary Gastrointestinal Stromal Tumors (GIST) in the Adjuvant Therapy Era
Supplementary Figure 3. Genomic risk groups versus tumor size and mitotic rate.
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from Novel Genomic Risk Stratification Model for Primary Gastrointestinal Stromal Tumors (GIST) in the Adjuvant Therapy Era
Supplementary Figure 2. Multivariate Cox regression survival analysis for primary gastric and small bowel GISTs represented by forest plots.
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from Novel Genomic Risk Stratification Model for Primary Gastrointestinal Stromal Tumors (GIST) in the Adjuvant Therapy Era
Supplementary Figure 2. Multivariate Cox regression survival analysis for primary gastric and small bowel GISTs represented by forest plots.
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Tables S1-S5 from Novel Genomic Risk Stratification Model for Primary Gastrointestinal Stromal Tumors (GIST) in the Adjuvant Therapy Era
Supplementary Table S1. Metastasis Frequencies by Traditional vs. Genomic Risk Stratification Supplementary Table S2. List of gene level and chromosomal arm level genomic variables used in OncoCast. Supplementary Table S3-S4. Frequencies of genomic alterations by OncoCast risk groups in primary gastric and small bowel GISTs. Supplementary Table S5. Number and frequencies of specific KIT/PDGFRA mutations in primary localized gastric and small bowel GISTs.
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Tables S1-S5 from Novel Genomic Risk Stratification Model for Primary Gastrointestinal Stromal Tumors (GIST) in the Adjuvant Therapy Era
Supplementary Table S1. Metastasis Frequencies by Traditional vs. Genomic Risk Stratification Supplementary Table S2. List of gene level and chromosomal arm level genomic variables used in OncoCast. Supplementary Table S3-S4. Frequencies of genomic alterations by OncoCast risk groups in primary gastric and small bowel GISTs. Supplementary Table S5. Number and frequencies of specific KIT/PDGFRA mutations in primary localized gastric and small bowel GISTs.
- Open Access
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from Novel Genomic Risk Stratification Model for Primary Gastrointestinal Stromal Tumors (GIST) in the Imatinib and Adjuvant Therapy Era
Supplementary Figure 2. Multivariate Cox regression survival analysis for primary gastric and small bowel GISTs represented by forest plots.
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from Novel Genomic Risk Stratification Model for Primary Gastrointestinal Stromal Tumors (GIST) in the Imatinib and Adjuvant Therapy Era
Supplementary Figure 2. Multivariate Cox regression survival analysis for primary gastric and small bowel GISTs represented by forest plots.
- Open Access
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Data from Novel Genomic Risk Stratification Model for Primary Gastrointestinal Stromal Tumors (GIST) in the Imatinib and Adjuvant Therapy Era
Purpose: Traditional risk stratification schemes in gastrointestinal stromal tumors (GIST) had been defined in the pre-imatinib era and rely solely on clinicopathologic metrics. We hypothesize that genomic-based risk stratification is prognostically relevant in the current era of tyrosine kinase inhibitor (TKI) therapeutics. Experimental Design: Comprehensive mutational and copy number profiling using MSK-IMPACT was performed. We integrated clinicopathologic and genomic parameters and utilized an elastic-net penalized Cox proportional hazards machine learning model for outcome risk stratification. Results: A 3-tier genomic risk stratification model for recurrence-free survival (RFS) in 152 primary localized gastric and 80 small bowel GISTs was proposed. Gastric GISTs were classified as high risk if chr1p deletion or SDHB loss was present, and intermediate risk if chr14q deletion was present or KIT exon 11 mutation was absent. Small bowel GISTs were classified as high risk if MAX/MGA/MYC, CDKN2A or RB1 alterations was present, and intermediate risk if chr1p deletion or chr5q amplification was present. Compared to conventional risk stratification, genomic risk stratification both upgrades and downgrades, suggesting that conventional risk stratification may underestimate or overtreat some high-risk and low-risk patients, respectively. Longitudinal sequencing detected most KIT-independent genomic alterations at baseline. Subanalysis in 26 SDH-deficient GISTs revealed that presence of TP53 mutations or chr1q amplifications portends worse RFS and disease-free survival. Conclusions: We developed a novel, next-generation genomic risk stratification model for primary gastric and small bowel GISTs, complementing traditional clinicopathologic models. Future independent validation of our model in external cohorts is essential.
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessData from Novel Genomic Risk Stratification Model for Primary Gastrointestinal Stromal Tumors (GIST) in the Imatinib and Adjuvant Therapy Era
Purpose: Traditional risk stratification schemes in gastrointestinal stromal tumors (GIST) had been defined in the pre-imatinib era and rely solely on clinicopathologic metrics. We hypothesize that genomic-based risk stratification is prognostically relevant in the current era of tyrosine kinase inhibitor (TKI) therapeutics. Experimental Design: Comprehensive mutational and copy number profiling using MSK-IMPACT was performed. We integrated clinicopathologic and genomic parameters and utilized an elastic-net penalized Cox proportional hazards machine learning model for outcome risk stratification. Results: A 3-tier genomic risk stratification model for recurrence-free survival (RFS) in 152 primary localized gastric and 80 small bowel GISTs was proposed. Gastric GISTs were classified as high risk if chr1p deletion or SDHB loss was present, and intermediate risk if chr14q deletion was present or KIT exon 11 mutation was absent. Small bowel GISTs were classified as high risk if MAX/MGA/MYC, CDKN2A or RB1 alterations was present, and intermediate risk if chr1p deletion or chr5q amplification was present. Compared to conventional risk stratification, genomic risk stratification both upgrades and downgrades, suggesting that conventional risk stratification may underestimate or overtreat some high-risk and low-risk patients, respectively. Longitudinal sequencing detected most KIT-independent genomic alterations at baseline. Subanalysis in 26 SDH-deficient GISTs revealed that presence of TP53 mutations or chr1q amplifications portends worse RFS and disease-free survival. Conclusions: We developed a novel, next-generation genomic risk stratification model for primary gastric and small bowel GISTs, complementing traditional clinicopathologic models. Future independent validation of our model in external cohorts is essential.
- Open Access
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3 from Novel Genomic Risk Stratification Model for Primary Gastrointestinal Stromal Tumors (GIST) in the Imatinib and Adjuvant Therapy Era
Supplementary Figure 3. Genomic risk groups versus tumor size and mitotic rate.
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S3 from Novel Genomic Risk Stratification Model for Primary Gastrointestinal Stromal Tumors (GIST) in the Imatinib and Adjuvant Therapy Era
Supplementary Figure 3. Genomic risk groups versus tumor size and mitotic rate.
- Open Access
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Tables S1-S5 from Novel Genomic Risk Stratification Model for Primary Gastrointestinal Stromal Tumors (GIST) in the Imatinib and Adjuvant Therapy Era
Supplementary Table S1. Metastasis Frequencies by Traditional vs. Genomic Risk Stratification Supplementary Table S2. List of gene level and chromosomal arm level genomic variables used in OncoCast. Supplementary Table S3-S4. Frequencies of genomic alterations by OncoCast risk groups in primary gastric and small bowel GISTs. Supplementary Table S5. Number and frequencies of specific KIT/PDGFRA mutations in primary localized gastric and small bowel GISTs.
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Tables S1-S5 from Novel Genomic Risk Stratification Model for Primary Gastrointestinal Stromal Tumors (GIST) in the Imatinib and Adjuvant Therapy Era
Supplementary Table S1. Metastasis Frequencies by Traditional vs. Genomic Risk Stratification Supplementary Table S2. List of gene level and chromosomal arm level genomic variables used in OncoCast. Supplementary Table S3-S4. Frequencies of genomic alterations by OncoCast risk groups in primary gastric and small bowel GISTs. Supplementary Table S5. Number and frequencies of specific KIT/PDGFRA mutations in primary localized gastric and small bowel GISTs.